Healthcare · Pharmaceuticals & Biotechnology
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).
Ranks #None of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 1 Sep 2026 | PRAKRUTI R PALI | Bulk | Buy | 51,000 | 123.0400 | BSE |
| 31 Aug 2026 | SNEHLATA MANOJ KATHOTIA | Bulk | Buy | 43,000 | 119.1000 | BSE |
| 31 Aug 2026 | PRAKRUTI R PALI | Bulk | Buy | 100,000 | 123.8800 | BSE |
| 28 Aug 2026 | PRAKRUTI R PALI | Bulk | Buy | 164,000 | 112.8100 | BSE |
| 27 Aug 2026 | PRAKRUTI R PALI | Bulk | Buy | 240,000 | 103.6900 | BSE |
| 26 Aug 2026 | PRAKRUTI R PALI | Bulk | Buy | 138,000 | 95.5900 | BSE |
| 20 Aug 2026 | SNEHLATA MANOJ KATHOTIA | Bulk | Buy | 67,000 | 81.6800 | BSE |
| 20 Aug 2026 | VANITA ANILKUMAR KUMBHARE | Bulk | Sell | 70,000 | 81.0400 | BSE |
| 17 Jul 2026 | DILIP RAMESHCHANDRA JAGAD | Bulk | Sell | 100,000 | 66.5500 | BSE |
| 12 Jun 2026 | PRAKRUTI R PALI | Bulk | Buy | 75,000 | 78.4100 | BSE |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 1 Oct 2026 | AGM/EGM | Asston Pharmaceuticals Ltd - 544445 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report |
| 1 Oct 2026 | Company Update | Asston Pharmaceuticals Ltd - 544445 - Announcement under Regulation 30 (LODR)-Change in Management |
| 1 Oct 2026 | Company Update | Asston Pharmaceuticals Ltd - 544445 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s |
| 29 Sep 2026 | AGM/EGM | Asston Pharmaceuticals Ltd - 544445 - Shareholder Meeting / Postal Ballot-Outcome of AGM |
| 27 Sep 2026 | Insider Trading / SAST | Asston Pharmaceuticals Ltd - 544445 - Closure of Trading Window |
| 5 Sep 2026 | Company Update | Asston Pharmaceuticals Ltd - 544445 - Announcement under Regulation 30 (LODR)-Allotment |
| 5 Sep 2026 | Others | Asston Pharmaceuticals Ltd - 544445 - Board Meeting Outcome for Allotment Of 24,10,431 Equity Shares Via Preferential Allotment |
| 4 Sep 2026 | AGM/EGM | Asston Pharmaceuticals Ltd - 544445 - Fixing 29Th September 2026 As The Date For Convening The 7Th Annual General Meeting Of The Company. |
| 4 Sep 2026 | Board Meeting | Asston Pharmaceuticals Ltd - 544445 - Board Meeting Outcome for Out Come Of The Board Meeting |
| 4 Sep 2026 | Company Update | Asston Pharmaceuticals Ltd - 544445 - Announcement under Regulation 30 (LODR)-Meeting Updates |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
